MD 920Alternative Names: MD 920G; MD-921
Latest Information Update: 15 Apr 2016
At a glance
- Originator Aus Bio Limited
- Mechanism of Action Cell stimulants; Growth modulators; Nitric oxide modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Glaucoma; Wounds
Most Recent Events
- 19 Apr 2010 Phase-I development is ongoing in Australia
- 06 Jan 2005 Phase-I clinical trials in Wounds in Australia (unspecified route)